Prime Medicine Inc (NASDAQ: PRME) on Friday, soared 8.02% from the previous trading day, before settling in for the closing price of $3.74. Within the past 52 weeks, PRME’s price has moved between $1.11 and $5.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -124.13% over the last five years. The company achieved an average annual earnings per share of 23.78%. With a float of $52.90 million, this company’s outstanding shares have now reached $131.16 million.
The firm has a total of 214 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.87%, operating margin of -496.2%, and the pretax margin is -485.69%.
Prime Medicine Inc (PRME) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prime Medicine Inc is 60.67%, while institutional ownership is 28.85%. The most recent insider transaction that took place on Aug 01 ’25, was worth 9,999,990. In this transaction Director of this company bought 3,030,300 shares at a rate of $3.30, taking the stock ownership to the 6,230,300 shares. Before that another transaction happened on Aug 01 ’25, when Company’s 10% Owner bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.47% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Prime Medicine Inc (PRME) is currently performing well based on its current performance indicators. A quick ratio of 4.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 141.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 4.41 million was better than the volume posted last year of 2.39 million. As of the previous 9 days, the stock’s Stochastic %D was 19.83%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 72.17%, which indicates a significant increase from 31.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.46 in the past 14 days, which was higher than the 0.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.77, while its 200-day Moving Average is $2.67. Now, the first resistance to watch is $4.24. This is followed by the second major resistance level at $4.43. The third major resistance level sits at $4.80. If the price goes on to break the first support level at $3.68, it is likely to go to the next support level at $3.31. Should the price break the second support level, the third support level stands at $3.12.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
Market capitalization of the company is 543.36 million based on 134,496K outstanding shares. Right now, sales total 2,980 K and income totals -195,880 K. The company made 1,450 K in profit during its latest quarter, and -51,890 K in sales during its previous quarter.
